Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2016 / N 1

Новые маркеры хронической сердечной недостаточности: аспекты воспаления (библиография)
И.И. Чукаева, Ф.Д. Ахматова, М.В. Хорева, Л.В. Ковальчук

1. Национальные рекомендации ВНОК И ОССН по диагностике и лечению ХСН (третий пересмотр). Сердечная недостаточность 2010; (1).
2. Lloyd-Jones D., Adams R.J., Brown T.M., De Simone G., Ferguson T.B., Flegal K., Ford E., Furie K., Go A., Greenlund K., Haase N., Hailpern S., Ho M., Howard V., Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M., Meigs J., Mozaffarian D., Nichol G., O'Donnell C., Roger V., Rosamond W., Sacco R., Sorlie P., Stafford R., Steinberger J., Thom T., Wasserthiel-Smoller S., Wong N., Wylie-Rosett J., Hong Y.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119(3): 480–486.
3. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., Strömberg A., van Veldhuisen D.J., Atar D., Hoes A.W., Keren A., Mebazaa A., Nieminen M., Priori S.G., Swedberg K.; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29(19): 2388–2442.
4. Fonarow G.C., Corday E.; ADHERE Scientific Advisory Committee. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 2004; 9(3): 179–185.
5. Kakkar R., Lee R.T. ST2 and adrenomedullin in heart failure. Heart Fail Clin 2009; 5(4): 515–527.
6. Dieplinger B., Gegenhuber A., Haltmayer M., Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilized heart failure in patients with shortness of breath. Heart 2009; 95(18): 1508–1513.
7. Weinberg E.O., Shimpo M., De Keulenaer G.W., MacGillivray C., Tominaga S., Solomon S.D., Rouleau J.L., Lee R.T. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106(23): 2961–2966.
8. McKinsey T.A., Olson E.N. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 2005; 115(3): 538–546.
9. Manabe I, Shindo T, Nagai R. Gene Expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 2002; 91(12): 1103–1113.
10. Iwahana H., Yanagisawa K., Ito-Kosaka A., Kuroiwa K., Tago K., Komatsu N., Katashima R., Itakura M., Tominaga S. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999; 264(2): 397–406.
11. Sanada S., Hakuno D., Higgins L., Schreiter E.R., McKenzie A.N., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117(6): 1538–1549.
12. Barksby H.E., Lea S.R., Preshaw P.M., Taylor J.J. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 2007; 149(2): 217–225.
13. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F., Kastelein R.A. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor – related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23(5): 479–490. 14. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7(10): 827–840.
15. Feldman A.M., Weinberg E.O., Ray P.E., Lorell B.H. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res 1993; 73(1): 184–192.
16. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009; 2(4): 311–319.
17. Weinberg E.O., Shimpo M., Hurwitz S., Tominaga S.I., Rouleau J.L., Lee R.T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003; 107(5): 721–726.
18. Sweet M.J., Leung B.P., Kang D., Sogaard M., Schulz K., Trajkovic V., Campbell C.C., Xu D., Liew F.Y. A novel pathway regulating lipopolysaccharideinduced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001; 166(11): 6633–6639.
19. Januzzi J.L., Peacock W.F., Maisel A.S., Chae C.U., Jesse R.L., Baggish A.L., O'Donoghue M., Sakhuja R., Chen A.A., van Kimmenade R.R., Lewandrowski K.B., Lloyd-Jones D.M., Wu A.H. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007; 50(7): 607–613.
20. Rehman S.U., Mueller T., Januzzi J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008; 52(18): 1458–1465.
21. Rehman S.U., Martinez-Rumayor A., Mueller T., Januzzi J.L. Jr. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin Chim Acta 2008; 392(1–2): 41–45.
22. Mueller T., Dieplinger B., Gegenhuber A., Poelz W., Pacher R., Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008; 54(4): 752–756.
23. Boisot S., Beede J., Isakson S., Chiu A., Clopton P., Januzzi J., Maisel A.S., Fitzgerald R.L. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008; 14(9): 732–738.
24. Pascual-Figal D.A., Ordoñez-Llanos J., Tornel P.L., Vázquez R., Puig T., Valdés M., Cinca J., de Luna A.B., Bayes-Genis A.; MUSIC Investigators. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009; 54(23): 2174–2179.
25. Shimpo M., Morrow D.A., Weinberg E.O., Sabatine M.S., Murphy S.A., Antman E.M., Lee R.T. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109(18): 2186–2190.
26. Sabatine M.S., Morrow D.A., Higgins L.J., MacGillivray C., Guo W., Bode C., Rifai N., Cannon C.P., Gerszten R.E., Lee R.T. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008; 117(15): 1936–1944.
27. Dieplinger В., Egger М., Haltmayer М., Kleber M.E., Scharnagl H., Silbernagel G., de Boer R.A., Maerz W., Mueller T. Increased Soluble ST2 Predicts Long-term Mortality in Patients with Stable Coronary Artery Disease: Results from the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem 2014; 60(3): 530–540.
28. Januzzi J.L. Jr., Camargo C.A., Anwaruddin S., Baggish A.L., Chen A.A., Krauser D.G., Tung R., Cameron R., Nagurney J.T., Chae C.U., Lloyd-Jones D.M., Brown D.F., Foran-Melanson S., Sluss P.M., Lee-Lewandrowski E., Lewandrowski K.B. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95(8): 948–954.
29. Dieplinger B., Januzzi J.L., Steinmair M., Gabriel C., Poelz W., Haltmayer M., Mueller T. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma – the Presage ST2 assay. Clin Chim Acta 2009; 409(1–2): 33–40.
30. Martinez-Rumayor A., Camargo C.A., Green S.M., Baggish A.L., O’Donoghue M., Januzzi J.L. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol 2008; 30(4): 578–584.
31. Алиева А.М., Булаева Н.И., Громова О.И., Голухова Е.З. Вариабельность сердечного ритма в оценке клинико-функционального состояния и прогноза при хронической сердечной недостаточности. Креативная кардиология 2015; (3): 42–55.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]